Transgene SA
TRGNF
$0.85
-$0.15-15.00%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 326.20% | 317.19% | -- | -- | -97.07% |
| Total Other Revenue | -8.02% | -10.43% | 43.83% | 32.22% | 50.12% |
| Total Revenue | -4.10% | -6.61% | 43.83% | 32.22% | -5.44% |
| Cost of Revenue | -7.41% | -9.84% | 22.45% | 12.57% | 33.17% |
| Gross Profit | 8.04% | 10.45% | -16.50% | -7.10% | -44.30% |
| SG&A Expenses | 20.29% | 17.13% | -12.49% | -19.54% | -15.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 1,144.44% | 1,110.39% | 55.91% | 59.43% | 59.15% |
| Total Operating Expenses | 1.68% | -0.98% | 14.94% | 5.66% | 23.13% |
| Operating Income | -2.59% | 0.10% | -9.05% | -0.26% | -29.24% |
| Income Before Tax | -13.85% | -10.86% | -23.42% | -13.46% | -169.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.85% | -10.86% | -23.42% | -13.46% | -169.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.85% | -10.86% | -23.42% | -13.46% | -169.44% |
| EBIT | -2.59% | 0.10% | -9.05% | -0.26% | -29.24% |
| EBITDA | -2.34% | 0.35% | -8.91% | -0.12% | -31.62% |
| EPS Basic | 3.69% | 6.20% | 6.03% | 13.54% | -106.45% |
| Normalized Basic EPS | 3.64% | 6.39% | 6.01% | 13.54% | -107.55% |
| EPS Diluted | 4.78% | 7.22% | 3.19% | 10.95% | -108.80% |
| Normalized Diluted EPS | 3.64% | 6.39% | 6.01% | 13.54% | -107.55% |
| Average Basic Shares Outstanding | 18.26% | 18.26% | 31.26% | 31.26% | 30.57% |
| Average Diluted Shares Outstanding | 18.26% | 18.26% | 31.26% | 31.26% | 30.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |